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Abstract
Specific absorption parameters for 239PuO2 and 238PuO2 have been determined based on available 
biokinetic data from studies in rodents, and the impacts of these parameters on bioassay 
interpretation and dosimetry after inhalation of nanoPuO2 materials have been evaluated. 
Calculations of activities after an acute intake of nanoparticles of 239PuO2 and 238PuO2 are 
compared with the corresponding calculations using standard default absorption parameters using 
the International Commission on Radiological Protection (ICRP) 66 respiratory tract model. 
Committed effective doses are also evaluated and compared. In this case, it was found that 
interpretation of bioassay measurements with the assumption that the biokinetic behaviour of 
PuO2 nanoparticles is the same as that of micrometre-sized particles can result in an 
overprediction of the committed effective dose by two orders of magnitude. Although in this case 
the use of the default assumptions (5 μm AMAD, Type S) for assessing dose following inhalation 
exposure to airborne PuO2 nanoparticles appears to be conservative, the evaluation of situations 
involving PuO2 nanoparticles that may have different particle size and solubility properties should 
prudently follow the ICRP recommendation to obtain and use additional, material-specific 
information whenever possible.
INTRODUCTION
Default blood absorption parameters for radionuclides in the lungs are described and 
discussed in International Commission on Radiological Protection (ICRP) Publication 66 on 
the Human Respiratory Tract Model (HRTM)(1). However, as pointed out in ICRP 
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Publication 30, if the behaviour of any specific material is expected to differ significantly 
from that of the biokinetic model employed, then the model parameters should be modified 
to take account of the available data(2). In the case of plutonium (Pu), a considerable number 
of studies involving Pu particles in the micrometre size range have demonstrated that in 
general plutonium dioxides (PuO2) behave as a Type S material(3). It is of interest to 
determine how the use of material-specific particle size and bioassay parameters for PuO2 
materials in the nanosize range might influence decision-making for health protection.
Traditional risk management of the biological effects and related health consequences of 
inhalation exposure to radionuclides such as PuO2 has relied on data and default 
assumptions from studies involving particles in the micrometre size range. Nonetheless, as 
work with nanometre-sized materials expands, it is reasonable to ask whether the biological 
behaviour of plutonium dioxide in the nanometre size range might differ significantly from 
its behaviour in the micrometre size range. While the current default values for biokinetic 
models are representative of the experience base for materials in the micrometre size range, 
there has been no assessment to date as to whether or not the use of the defaults would be 
protective for someone exposed to 239PuO2 and 238PuO2 in the nanosize range. Correct 
assessment of the biokinetic behaviour of Pu following an inhalation exposure requires 
determination of when default assumptions are adequate or when material-specific 
information is needed.
The impacts using specific absorption parameters for 239PuO2 and 238PuO2 and the impacts 
on bioassay interpretation and dosimetry after inhalation of nanoPuO2 materials need to be 
evaluated. To address this, historical data on the biokinetic behaviour of Pu observed in rats, 
exposed by pulmonary intubation to plutonium dioxide (PuO2) nanoparticles, are used to 
derive specific blood absorption parameters for use with the HRTM published by the ICRP, 
ICRP Publication 66. This work illustrates the use of material-specific particle size and 
bioassay parameters with corresponding bioassay tables and dose coefficients. Calculations 
of activities after an acute intake of nanoparticles of 239PuO2 and 238PuO2 are compared 
with the corresponding calculations using standard default absorption parameters using the 




There are no human data available to assess absorption of PuO2 from nanometre-sized 
particles in the respiratory tract. Therefore, biokinetic information must be derived from 
experiments with laboratory animals, notably the studies conducted by Smith et al. 
with 239PuO2 nanoparticles and Stradling et al. with 238PuO2 nanoparticles(4, 5).
According to Smith et al., size-fractionated 239Pu particles that were produced by arc 
vaporisation of a Pu metal wire were obtained by membrane filtration into sizes <25 nm, 25–
220 nm and 220 nm to 1.2 μm physical diameters. Separation of particles in the <25 nm 
suspension via membrane filtration with nominal pore diameters of 12, 9, 6 and 4 nm were 
attempted but were not successful(4). However, ultrafiltration through a membrane with a 
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nominal pore size of 1 nm was successful, indicating that the particle size in the <25 nm 
suspension was primarily uniform with a diameter of 1 nm(4). Particles in the largest size 
range (220 nm to 1.2 μm) were not used in the Smith et al. pulmonary intubation study. 
Stradling et al., using the same filtration method used in Smith et al., prepared size-
fractionated 238Pu particles of fresh and aged (32 weeks) particles into four particle size 
ranges <25 nm, 25–220 nm and 220 nm to 1.2 μm, and 1.2–5 μm diameters. Stradling et al. 
attempted to fractionate the particle sizes in the <25 nm suspension and found through 
electron microscopy and ultrafiltration that the <25 nm suspension of 238PuO2, like 
the 239PuO2 <25 nm suspension analysed by Smith et al., consisted primarily of 1 nm 
particles. Stradling et al. only used the <25 nm particles for their pulmonary intubation 
study.
Rats in both studies were administered the suspensions of PuO2 nanoparticles by pulmonary 
intubation through a cannula temporarily inserted into the trachea. Following exposure, 
animals were immediately put into metabolism cages to allow for the separate collection of 
urine and faeces and were given access to food and water at all times. After exposure, the 
groups of animals exposed to 239PuO2 were sacrificed at 18 h, 6 d and 17 d, while the 
groups of animals exposed to 238PuO2 fresh and aged suspensions were sacrificed at 1, 6 and 
21 d(4, 5). For both studies, there were four animals in each group except for a group of eight 
animals that were sacrificed on Day 17 of the 239PuO2 study. To analyse the plutonium 
distribution in various tissues, Smith et al. collected urine and faeces over the course of their 
study and separated out the animal’s lungs, liver, spleen, blood, carcase and other tissues 
(kidneys, testes, adrenals, thymus and gastrointestinal tract) at the time of sacrifice. Stradling 
et al. collected urine and faeces over the course of their study and separated out the lungs, 
liver, blood, carcase and other tissues (spleen, kidneys, ovaries and gastrointestinal tract) at 
the time of sacrifice.
Equivalent aerodynamic diameter
Plutonium dioxide nanoparticle sizes in Smith et al. and Stradling et al. were reported as 
physical diameter based on size separation of the particles by filtration and examination of 
the separated particles by electron microscopy(4, 5). Smith et al. reported a uniform physical 
size of 1 nm for particles <25 nm and a mass median diameter of 48 nm for material in the 
25–220 nm size range. Stradling et al. also reported a uniform 1 nm particle diameter for 
particles <25 nm. Conversion of physical diameters to an equivalent aerodynamic diameter 
was done using the equations in Section D.4.1 in Annexe D of ICRP Publication 66(1). For 
the calculation, the density of plutonium was assumed to be 9 g cm−3 and the shape factor 
was assumed to be 1. The aerodynamic diameters of plutonium nanoparticles were 
calculated to be 9 and 258 nm for 1 and 48 nm diameter particles, respectively. Thus, for the 
purposes of calculating daily urinary excretion and dose, nominal particle sizes were taken 
to be 1 and 48 nm when expressed in terms of activity median thermodynamic diameter 
(AMTD) and 10 and 250 nm when expressed in terms of activity median aerodynamic 
diameter (AMAD). For the purposes of presenting data in this paper in a uniform way across 
the wide particle size range from 5 um AMAD (the default work-place diameter) to 1 nm 
physical diameter, the authors have chosen to present graphical and tabular results in terms 
of AMAD. Many workplace studies involving cascade impaction provide particle size 
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distributions in terms of aerodynamic diameter. It is appropriate to express particle sizes for 
nanoparticles in terms of AMTD, and some data based on diffusion analysers are available 
for some workplace situations. However, AMAD correspondences will be used throughout 
this paper for purposes of comparison of calculation results.
Determination of material-specific blood absorption parameters
Lung and systemic biokinetic models for the rat, shown in Figure 1, were developed to fit 
the available experimental data. The systemic portion of the model was based on the current 
ICRP plutonium systemic model for humans(6). Recycling of plutonium in organs to and 
from blood has also been taken into account. The model contains blood, liver1 (which 
describes biliary excretion), liver2 (which describes recycling back to blood and biliary 
excretion), carcase and other (other soft tissues). The main difference from the ICRP 
plutonium systemic model and the rat model developed here is that only prompt urinary 
excretion to the urinary bladder was considered without considering retention in the kidney 
compartment because the amount of available data was insufficient to support the inclusion 
of this pathway. To distinguish it from data in other soft tissues, a separate ‘carcase’ 
compartment was generated, which encompasses skeletal Pu content as well as that in 
attached undissected muscle tissue.
Transfer rates for the systemic portion of the model were derived from the intravenous 
injection experiments conducted by Smith et al.(4). Transfer rates derived for 239Pu can be 
seen in Table 1, and 238Pu results are shown in Table 2. In this work, two lung 
compartments, named Lung1 and Lung2, were added to the systemic model to represent the 
transfer processes from particles in initial state to blood (sp) and to particles in transformed 
state (spt) and from particles in transformed state to blood (st). Regarding the transfer rates 
presented in Table 1, at first glance one would expect a greater transfer of materials from 
smaller particles due to their higher surface area when compared with larger particles that 
have a smaller surface-to-mass ratio. However, there are several pathways involved in this 
recycling model, so the fitting process involves the overall examination of transfer as a 
whole and not by individual transfer rates. In addition, it is recognised that the same 
metabolism can be described by different combinations of transfer rates.
RATDOSE software was used to determine the material-specific blood absorption 
parameters(7). It is a software application that was developed to provide the ability to 
empirically model the biokinetics of radionuclides administered in animal experiments. The 
software allows the user to produce a computational framework in which complex 
compartmental models together with tissue and excreta activity data can be fitted with 
fidelity thus minimising the uncertainties in the predictions. It has a robust statistical 
treatment of the data and good presentation of the results. Goodness of fit for how well the 
model describes the available data is assessed through the determination of χ2.
Activities and dose calculations
Activities predicted in organs and excreta for standard workers following acute inhalation of 
PuO2 for both isotopes 239Pu and 238Pu for AMADs 5 μm Types M and S, particles of 
physical diameter 1 nm (10 nm AMAD) of each isotope, and particles in the 25–220 nm 
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diameter range (250 nm AMAD) for 239Pu were evaluated using a software package (AIDE) 
that calculates activities in compartments and committed doses due to intakes of 
radionuclides(8). In this work, inhalation intakes of plutonium were calculated using the 
ICRP HRTM(1) together with the ICRP Publication 67 plutonium systemic model(6). Output 
of the AIDE model is in terms of daily urinary excretion activities and corresponding 
committed dose coefficients for 239Pu and 238Pu. Committed effective dose coefficients 
(e50) per unit measured activity in daily urinary excretion (Sv Bq−1), also known as dose per 
unit content, were calculated using AIDE for acute intakes of 239Pu and 238Pu for several 
particle sizes and solubilities.
RESULTS AND DISCUSSION
Data extracted from the studies for 239Pu and 238Pu oxides of 1 nm diameter size (10 nm 
AMAD) and for 239Pu oxide in the particle size range of 25–220 nm (250 nm AMAD) were 
entered into RATDOSE software. Initial fittings of transfer rates sp, spt and st were done 
using 239Pu data with a corresponding χ2 per degree of freedom of 3.0 for 10 nm AMAD 
particles. Fitting of sp, spt and st for 238Pu are also shown in Table 3, with corresponding χ2 
per degree of freedom of 6.3 for fresh and 8.4 for aged materials, which are not as good as 
the one obtained for 10 nm AMAD particles of 239Pu. For larger particles of 250 nm 
AMAD, the corresponding χ2 per degree of freedom was 29.7 as also shown in Table 3. 
While unsatisfactory in terms of the χ2 result, it is probably enough to show that larger 
particles present much longer lung retention as can be seen by the st value of 1.2 × 10−5 d−1, 
which corresponds to a biological half-life of roughly 158 y. It must be noted though that 
this number was derived using data points for times only up to 17 d. The results for the 
larger particle sizes should therefore be interpreted with caution.
The derived blood absorption parameters for 239Pu shown in Table 3 for particles of 10 nm 
AMAD are similar to those presented by Davesne et al.(9) who followed the 
recommendations of the ICRP Supporting Guidance 3(10) for using the systemic model for 
plutonium in the rat when obtaining material-specific blood absorption parameters. In 
Supporting Guidance 3, a much simpler model is proposed in which activity leaves the blood 
at a rate of 280 d−1 (half-time ~4 min). Of this, ~70 % is deposited in body tissues that 
correspond to the ‘carcase’, from which it clears at a rate of 0.003 d−1 (half-time ~230 d)(10). 
The blood absorption parameters were calculated using the same data, but the results from 
Davesne et al.(9) were presented using the alternate representation for the blood absorption 
process through fr, sr and ss parameters. Comparison of the sp, spt and st results calculated in 
this work with those converted from Davesne et al. values(9), using the relationship 
conversion sr = sp ± spt, fr = (sp − st) / (sp ± spt − st) and ss = st and are shown in the last 
column of Table 3. The results for 239PuO2 are remarkably similar, despite the use of 
completely different methods. The results for 238PuO2 appear different, mainly with an order 
of magnitude slower removal rate (sp) from the initial state to blood and higher retention 
shown for particles being absorbed from the transformed state to blood (st).
Using AIDE software(8) for comparison, Figure 2 shows the calculated daily urine excretion 
as a fraction of inhaled activity for 239Pu for AMADs 5 μm Types M and S and AMADs of 
250 and 10 nm using the calculated specific blood absorption parameters. The figure shows 
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that fraction of activity excreted in urine for the specific materials is larger than that for the 
default Type S material. As expected, the urinary excretion associated with a larger particle 
size AMAD 250 nm appears closer to the behaviour of a more soluble Type M material. The 
corresponding daily urine excretion as a fraction of inhaled activity was also calculated 
for 238Pu with the same magnitude difference as found for 239Pu.
Committed effective dose coefficients (e50) (Sv.Bq−1) and committed equivalent dose 
coefficients for body organs were calculated for acute intakes of plutonium dioxide for 
several particle sizes and solubilities. The committed effective dose coefficients and the 
committed equivalent dose coefficients for bone surface and for extrathoracic region (ET) 
are shown in Table 4. In most cases, the highest committed equivalent dose occurs for bone 
surface. The committed effective dose for inhalation intakes of 239Pu compounds associated 
with nanoparticles of AMAD 10 nm is ~34 times higher than that for Type S compounds 
with AMAD 5 μm, as seen in Table 4.
At first glance, the significant difference in the committed effective dose coefficient could 
impact the setting of operational radiation exposure limits in the field since the same activity 
measured in a filter will be associated with a higher dose when treated as a nanoparticle 
material. However, when a dose assessment is performed through urine bioassay 
measurements, a smaller committed effective dose per unit of 239Pu activity measured in a 
daily urinary excretion sample will be calculated for nanoparticles when compared with 
Type S materials, as shown in Figure 3. It can be seen that the dose per unit content curves 
as a function of time after intake for 5 μm Types M and for nanoparticles of AMAD 10 and 
250 nm using specific absorption parameters are similar and show smaller values than those 
for Type S compounds. The reason is because even having committed effective dose 
coefficients for inhalation of nanoparticles higher than that for Type S material, when it is 
divided by the much higher daily urinary excreted activity values for nanoparticles it results 
in smaller values for the ratios. It must be pointed out that the concept of dose per unit 
urinary excretion content is very useful for explaining the differences in committed effective 
dose coefficients for the several types of material when the intake estimates are made 
through urinalysis. However, committed dose estimates due to intakes of radionuclides using 
in vivo or in vitro techniques are mostly done in practice by initially performing the intake 
amount estimate and then using committed effective dose coefficients per unit intake to 
calculate the committed doses.
Figure 4 shows the comparison among the committed effective dose coefficients (e50) per 
unit measured activity in daily urinary excretion (Sv Bq−1) for acute intakes of 239Pu for the 
environmentally relevant AMADs 1 μm Types F, M and S with the AMADs 250 and 10 nm 
using specific blood absorption parameters derived from rat pulmonary intubation studies. 
The 1 μm Type F and AMAD 10 nm specific curves overlap. For the material evaluated in 
this study, it was concluded that in the absence of bioassay data tables, which were derived 
using material-specific absorption parameters, practitioners could use AMAD 1 μm Type F 
tables to reasonably interpret results for PuO2 particles in the AMAD 10 nm diameter size 
range. Based on data for the larger nanoparticles evaluated in this study, a more reasonable 
interpretation of bioassay measurements can be achieved by using intake retention fraction 
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tables derived for materials with a greater degree of solubility than the default Type S 
materials and a smaller particle size.
Nevertheless, studies with other materials are needed to determine if these observations are 
generally applicable.
CONCLUSIONS
Material-specific blood absorption parameters have been derived for PuO2 in the nanometre 
size range from pulmonary intubation experiments in rats(11). Using ICRP HRTM default 
parameters in the micrometre size range for PuO2 to predict biokinetic behaviour of PuO2 
following inhalation of Pu nanoparticles of AMAD 10 and 250 nm would underpredict the 
urinary excretion of plutonium. For 239Pu and 238Pu material of AMAD 10 nm and 239Pu of 
AMAD 250 nm, a higher urinary excretion of plutonium is likely to occur compared with 
excretion associated with Type S material of the default occupationally relevant particle size 
of 5 μm. The daily urinary excretion activity values for nanoparticles with an AMAD of 10 
nm are about two orders of magnitude higher than those for a typical 5 μm Type S material. 
These conclusions assume that the biokinetic behaviours noted in the previously described 
rat studies are predictive of biokinetics in humans exposed to similarly produced Pu aerosols 
and having similar particle size distributions.
Interpretation of bioassay measurements from individuals exposed to PuO2 nanoparticles 
with the assumption that the biokinetic behaviour of PuO2 nanoparticles is the same as that 
of micrometre-sized Pu particle parameters can result in an overprediction of the committed 
effective dose by two orders of magnitude. Consequently, intakes and committed effective 
doses could be overestimated from bioassay measurements if the materials contained in the 
exposure were known to be in the nanoparticle size range and Type S absorption parameters 
were assumed.
The committed effective dose for inhalation intakes of 239Pu materials associated with 
nanoparticles is higher than that for Type S materials with AMAD 5 μm if air measurements 
are used for interpretation. However, a smaller committed effective dose will be calculated 
when the dose assessment is performed based on urinary excretion measurements. Although 
in this case the use of the default assumptions (5 μm AMAD, Type S) for assessing dose 
following inhalation exposure to airborne PuO2 nanoparticles appears to be conservative, the 
evaluation of situations involving PuO2 nanoparticles that may have different particle size 
and solubility properties should prudently follow the ICRP recommendation to obtain and 
use additional, material-specific information whenever possible.
Additional biokinetic studies of AMADs between 10 and 250 nm would be helpful to 
determine the size at which the transition from Type S to a more soluble behaviour occurs. 
Such information would provide a stronger basis for determining when the HRTM default 
assumptions are adequate and when material-specific information is needed to correctly 
assess biokinetic behaviour associated with an inhalation exposure.
Analyses in the current work show that use of those default parameters to predict biokinetic 
behaviour of Pu following inhalation of PuO2 nanoparticles can result in an underprediction 
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of the urinary excretion of plutonium. Thus, continuing the current practice of using the 
traditional default assumptions for assessing dose following inhalation exposure to airborne 
PuO2 nanoparticles appears to be conservative, and therefore can be justified as prudent in 
the absence of additional, material-specific information.
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A lung and a systemic Pu biokinetic model for the rat.
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Comparison of calculated daily urine excretion as a fraction of inhaled activity for 239Pu 
using the default 5 μm AMAD with Type M and S blood absorption parameters and using 
the AMAD 250 nm and AMAD 10 nm with corresponding material-specific blood 
absorption parameters.
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Comparison of the calculated dose coefficient (e50 in Sv) per unit measured activity in daily 
urinary excretion (Bq) for inhaled 239Pu using the default 5 μm AMAD Type M and S and 
blood absorption parameters and using the AMAD 250 nm and AMAD 10 nm material-
specific blood absorption parameters.
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Calculated influence of assumed absorption type on the dose coefficient (e50 in Sv) per unit 
measured activity in daily urinary excretion (Bq) for inhaled 239Pu of 1 μm AMAD Type F, 
M, and S, and for inhaled 239Pu of 250 nm AMAD and 10 nm AMAD with the 
corresponding material-specific parameters.
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Table 1
Transfer rates for the rat Pu systemic model used in the fitting of 239Pu blood absorption parameters using 
RATDOSE software.
Source Target Transfer rate (d−1) for AMAD 250 nm Transfer rate (d−1) for AMAD 10 nm
Blood Urine 6.22 × 10−2 4.80 × 10−1
Blood Liver1 9.34 4.46 × 10−1
Blood Liver2 1.34 × 10−3 3.09 × 10−1
Liver1 GIT 2.58 × 10−2 3.90 × 10−2
Liver2 GIT 10.0 10.0
GIT Blood 2.86 × 10−1 6.29 × 10−5
GIT Faeces 4.00 × 10−1 1.15 × 10−1
Liver2 Blood 1.79 × 10−6 9.57 × 10−1
Blood Carcase 8.16 × 10−1 3.38
Carcase Blood 2.85 × 10−2 2.67 × 10−5
Blood Other 10.6 3.66 × 10−4
Other Blood 20.6 4.52 × 1016
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Table 2
Transfer rates for the rat Pu systemic model used in the fitting of 238Pu blood absorption parameters using 
RATDOSE software.
Source Target Transfer rate (d−1) for AMAD 10 nm Transfer rate (d−1) for AMAD 10 nm (aged)
Blood Urine 4.40 × 10−1 3.32 × 10−1
Blood Liver1 4.78 × 10−1 5.80 × 10−1
Blood Liver2 1.48 2.92 × 10−1
Liver1 GIT 3.95 × 10−2 3.63 × 10−2
Liver2 GIT 10.0 10.0
GIT Blood 8.54 × 10−5 7.66 × 10−5
GIT Faeces 2.01 × 10−1 2.15 × 10−1
Liver2 Blood 47.3 3.35
Blood Carcase 1.87 2.07
Carcase Blood 6.88 × 10−12 6.88 × 10−12
Blood Other 4.39 × 10−4 4.39 × 10−4
Other Blood 5.43 × 1016 5.42 × 1016
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Table 3
Specific blood absorption parameters calculated for inhaled plutonium materials.
Material AMAD (nm) Specific blood absorption parameters (d−1) χ2/n Data Specific blood absorption parameters (d−1) 
Davesne et al.
239PuO2 250 sp = 0.25
spt = 0.51
st =1.2 × 10−5
29.71 Not available
10 sp = 75.7
spt = 33.8
st =1.7 × 10−2
2.99 sp = 64
spt = 36
st =1.6 × 10−2
238PuO2 10 sp = 12.8
spt = 7.0
st =2.1 × 10−2
6.27 sp = 1.5
spt = 1.0
st = 3.3 × 10−3
10 (aged) sp = 22.7
spt = 16.0
st =2.3 × 10−2
8.42 sp =2.0
spt =1.1
st =9.2 × 10−3
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